Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients

Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient

“…There have been 3 patients with MCC who were reportedly treated with T-VEC in combination with PD-1/PD-L1 ICI, and all patients achieved a clinical response. 4 , 5 , 6 , 7 T-VEC has also been used safely in a solid organ transplant patient with melanoma. 8 To our knowledge, this is the first case of successful treatment of MCC in a patient with a history of solid organ transplant using oncolytic virus therapy.…”

Talimogene laherparepvec can initiate plasma cell invasion into infiltrated melanoma lesions – a case series

“…In addition, it has been reported that T‐VEC can provoke the occurrence of plasmacytoma in close proximity to the injection site 4 . In addition, this phenomenon has also been reported in Merkel cell carcinoma suggesting that this might not be related to melanoma‐specific T‐VEC application 5 …”

Immunotherapy for Merkel cell carcinoma

“…Tamilogene laherparepvec (T‐VEC) is an oncolytic viral immunotherapy which promotes tumor cell lysis leading to antigen release and proinflammatory signaling. It is FDA approved for unresectable in‐transit and regional melanoma and has been shown to induce both local responses and abscopal effect on distant untreated lesions 49,50 . Several trials are investigating the safety and efficacy of T‐VEC alone (NCT03458117), with radiation (NCT02819843), or in combination with the checkpoint inhibitor nivolumab (NCT02978625) in patients with MCC.…”